An unprecedented situation in global equity markets

Harris Associates have been awarded ‘Best Fund Provider’ for value equity and ‘Highly Commended’ for US equity.

As obesity rates swell worldwide, popular GLP-1 (Glucagon-like peptide-1) drugs such as Ozempic and Wegovy have generated investor interest.

Although the US equity market is very expensive and its first-half performance very concentrated, it still offers opportunities for a value and conviction-based investor like Harris Associates, who is convinced of the value of its investment process and able to avoid the political uncertainties that can affect the markets.